Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy
- PMID: 31486345
- PMCID: PMC6755139
- DOI: 10.1177/1744806919878088
Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy
Abstract
Background: The major dose-limiting toxicity of paclitaxel, one of the most commonly used drugs to treat breast cancer, is peripheral neuropathy (paclitaxel-induced peripheral neuropathy). Paclitaxel-induced peripheral neuropathy, which persists into survivorship, has a negative impact on patient’s mood, functional status, and quality of life. Currently, no interventions are available to treat paclitaxel-induced peripheral neuropathy. A critical barrier to the development of efficacious interventions is the lack of understanding of the mechanisms that underlie paclitaxel-induced peripheral neuropathy. While data from preclinical studies suggest that disrupting cytoskeleton- and axon morphology-related processes are a potential mechanism for paclitaxel-induced peripheral neuropathy, clinical evidence is limited. The purpose of this study in breast cancer survivors was to evaluate whether differential gene expression and co-expression patterns in these pathways are associated with paclitaxel-induced peripheral neuropathy.
Methods: Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology were identified between survivors who received paclitaxel and did (n = 25) or did not (n = 25) develop paclitaxel-induced peripheral neuropathy.
Results: Pathway impact analysis identified four significantly perturbed cytoskeleton- and axon morphology-related signaling pathways. Weighted gene co-expression network analysis identified three co-expression modules. One module was associated with paclitaxel-induced peripheral neuropathy group membership. Functional analysis found that this module was associated with four signaling pathways and two ontology annotations related to cytoskeleton and axon morphology.
Conclusions: This study, which is the first to apply systems biology approaches using circulating whole blood RNA-seq data in a sample of breast cancer survivors with and without chronic paclitaxel-induced peripheral neuropathy, provides molecular evidence that cytoskeleton- and axon morphology-related mechanisms identified in preclinical models of various types of neuropathic pain including chemotherapy-induced peripheral neuropathy are found in breast cancer survivors and suggests pathways and a module of genes for validation and as potential therapeutic targets.
Keywords: Chemotherapy; axon morphology; breast cancer; cytoskeleton; gene co-expression network analysis; gene expression; paclitaxel; pathway impact analysis; peripheral neuropathy; signaling pathway; survivor.
Figures



Similar articles
-
Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.J Neuroimmunol. 2019 Oct 15;335:577019. doi: 10.1016/j.jneuroim.2019.577019. Epub 2019 Aug 2. J Neuroimmunol. 2019. PMID: 31401418 Free PMC article.
-
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).Pharmacogenomics J. 2014 Aug;14(4):336-42. doi: 10.1038/tpj.2014.2. Epub 2014 Feb 11. Pharmacogenomics J. 2014. PMID: 24513692 Free PMC article. Clinical Trial.
-
Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors.Mol Pain. 2018 Jan-Dec;14:1744806918816462. doi: 10.1177/1744806918816462. Epub 2018 Nov 14. Mol Pain. 2018. PMID: 30426838 Free PMC article.
-
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.Exp Neurol. 2020 Feb;324:113121. doi: 10.1016/j.expneurol.2019.113121. Epub 2019 Nov 21. Exp Neurol. 2020. PMID: 31758983 Free PMC article. Review.
-
Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy.Int J Mol Sci. 2021 Aug 13;22(16):8733. doi: 10.3390/ijms22168733. Int J Mol Sci. 2021. PMID: 34445439 Free PMC article. Review.
Cited by
-
Peripheral Neuroinflammation and Pain: How Acute Pain Becomes Chronic.Curr Neuropharmacol. 2024;22(1):6-14. doi: 10.2174/1570159X21666230808111908. Curr Neuropharmacol. 2024. PMID: 37559537 Free PMC article. Review.
-
Perturbations in Endocytotic and Apoptotic Pathways Are Associated With Chemotherapy-Induced Nausea.Biol Res Nurs. 2021 Apr;23(2):238-247. doi: 10.1177/1099800420951271. Epub 2020 Aug 20. Biol Res Nurs. 2021. PMID: 32815385 Free PMC article.
-
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.J Transl Med. 2022 Dec 6;20(1):564. doi: 10.1186/s12967-022-03754-4. J Transl Med. 2022. PMID: 36474270 Free PMC article.
-
Pharmacologic Management of Persistent Pain in Cancer Survivors.Drugs. 2022 Feb;82(3):275-291. doi: 10.1007/s40265-022-01675-6. Epub 2022 Feb 17. Drugs. 2022. PMID: 35175587 Free PMC article. Review.
-
Chemotherapy for pain: reversing inflammatory and neuropathic pain with the anticancer agent mithramycin A.Pain. 2024 Jan 1;165(1):54-74. doi: 10.1097/j.pain.0000000000002972. Epub 2023 Jun 27. Pain. 2024. PMID: 37366593 Free PMC article.
References
-
- Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book 2015; 35: e553–e560. - PubMed
-
- Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O’Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: screening for cancer and treatment effects, version 2.2014. J Natl Compr Canc Netw 2014; 12: 1526–1531. - PMC - PubMed
-
- Kvale E, Urba SG. NCCN guidelines for survivorship expanded to address two common conditions. J Natl Compr Canc Netw 2014; 12: 825–827. - PubMed
-
- Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 2014; 22: 2261–2269. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical